The Company has now sold four BSD-2000 systems since Linden obtained Taiwan Food and Drug Administration (TFDA) marketing approval in February 2014.

"We are pleased to have successfully sold four BSD-2000 systems to Linden in fiscal year 2014," stated Sam Maravich, Vice President of International Sales and Marketing of BSD Medical.

"Linden remains very excited about the potential market for hyperthermia treatment in Taiwan. Linden is making inroads with notable key opinion leaders in Taiwan, which should help expand awareness of the clinical benefits of the BSD-2000 throughout Asia," concluded Mr. Maravich.

The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy.

The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region.

The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.